Synthon contracts Antitope for ADC testing

Related tags Immunology Immune system Cancer

Synthon contracts Antitope for ADC testing
Synthon has called on UK immunogenicity testing firm Antitope to analyze its pipeline of antibody drug conjugate (ADC) candidates.

The Antitope EpiScreen platform consists of pooled peripheral mononuclear blood cells (PMBCs) derived from multiple donors which, when exposed to drug candidates, exhibit a measurable immune response.

The aim of the deal is to determine the immunogenicity of the antibody part of the ADCs according to Synthon CSO, Marco Timmers, who said the tech will “reduce the risk that Synthon's antibody based development candidates will induce immunogenic responses​.”

Synthon’s ADC programme – which is based the manufacturing facility it opened in Nijmegen, the Netherlands in 2013 – is focused on breast cancer tumours that over-express the protein marker HER2.

The collaboration follows weeks after Antitope was called in to develop a manufacturing cell line for a novel dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer being developed by the Baylor Institute for Immunology Research (BIIR).

It also follows a string of biopharmaceutical collaborations agreed by Antitope’s parent company Abzena, including the deal signed by its other subsidiary Polytherics and developer Macrogenics in April.

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us

Webinars